The placebo-controlled, relapse prevention studies (PCRPS) have recently been recently been singled out as redundant, disproportionately harmful, unnecessary and therefore ethically impermissible (1). The logic of comparison behind PCRPS has also been questioned as they apply different methodological procedures, such as duration of treatment prior to randomization and/or different treatment discontinuation strategies (2). Furthermore, there seems to be a real threat that withdrawal syndromes and other overlapping phenomena (such as rebound effects) cannot be reliably distinguished from relapse (as primary endpoint), and as such have high confounding potential (2). This article is protected by copyright. All rights reserved.

中文翻译：

---

安慰剂在精神分裂症复发预防研究中的使用：科学还是伦理辩论？

最近，安慰剂对照的预防复发研究 (PCRPS) 被认为是多余的、有害的、不必要的，因此在伦理上是不允许的 (1)。PCRPS 背后的比较逻辑也受到质疑，因为它们采用不同的方法程序，例如随机化之前的治疗持续时间和/或不同的治疗中断策略 (2)。此外，戒断综合征和其他重叠现象（如反弹效应）似乎无法与复发（作为主要终点）可靠地区分，因此具有很高的混淆可能性（2）。本文受版权保护。版权所有。